psalexa
P&S Market Research - A market research firm

Acute Leukemia Therapeutics Pipeline Analysis

Acute Leukemia Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11214
Available Format:

Acute leukemia is also known as cancer of blood cells in which immature blood cells modify into cancer cells. The disease arises from bone marrow and causes formation of numerous large blood cells. Leukemia is categorized into five different types namely acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, and hairy cell leukemia. Leukemia can produce be symptoms such as fever, recurrent nosebleeds, bone pain, swollen lymph nodes, persistent fatigue, petechiae, and weight loss. Some of the risk factors associated with acute leukemia are smoking, exposure to benzene, previous cancer treatment such as chemotherapy and radiation therapy, and family history. Gilead Sciences, Inc. is in the process of developing entospletinib as a Syk inhibitor for the treatment of acute leukemia. Medigene AG is in the process of developing DC vaccine for the treatment of acute leukemia. Some of the companies having pipeline of acute leukemia include Ono Pharmaceutical Co. Ltd., Prescient Therapeutics, Ltd., Oncoceutics, Inc., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry